Littérature scientifique sur le sujet « Jpsat »

In 1990, the Japanese Political Science Association (JPSA) and the APSA initiated a formal exchange program. Every year, the JPSA invites APSA representatives to attend our annual meeting—where they have a joint session with Japanese members—and sends two JPSA representatives to the APSA Annual Meeting. In 2004, APSA President Margaret Levi (University of Washington) and Ian Shapiro (Yale University) attended the JPSA meeting in Sapporo; the JPSA exchange participants in the APSA Annual Meeting in Chicago were Ryosuke Amiya (Kobe University) and Kensuke Takayasu (Hokkaido University).

Temporal Jump Point Search (JPST) is a recently introduced algorithm for grid-optimal pathfinding among dynamic temporal obstacles. In this work we consider JPST as a low-level planner in Multi-Agent Path Finding (MAPF). We investigate how the canonical ordering of JPST can negatively impact MAPF performance and we consider several strategies which allow us to overcome these limitations. Experiments show our new CBS/JPST approach can substantially improve on CBS/SIPP, a contemporary and leading method from the area.

BackgroundChildren with juvenile psoriatic arthritis (JPsA) are treated similarly to patients in other categories of juvenile idiopathic arthritis (JIA) despite distinctive clinical features, including either a personal or family history of psoriasis. It remains unknown whether the unique features in JPsA lead patients to experience the impact of disease differently from other JIA patients, and how the presence of psoriasis within JPsA affects patient outcomes. These gaps in our knowledge suggest there may be unmet treatment needs in these children and young people.ObjectivesTo compare patient-reported outcomes in patients with JPsA and other JIA categories. Additionally, this study explores whether the presence or absence of psoriasis in patients with JPsA is associated with different outcomes.MethodsChildren and young people with JIA were selected if recruited to the Childhood Arthritis Prospective Study (CAPS), a UK multicentre inception cohort of JIA, between January 2001 and March 2018. Detailed demographic information, clinical data and patient-reported outcomes were collected at initial presentation to paediatric rheumatology. Patient-reported outcomes included well-being as measured on the parental global evaluation (10cm), functional ability (Childhood Health Assessment Questionnaire: CHAQ), pain (10cm), health-related quality of life (Child Health Questionnaire, CHQ psychosocial score), depressive symptoms (Mood and Feelings Questionnaire, MFQ) and parent psychosocial health (General Health Questionnaire: GHQ). The CHQ and MFQ questionnaires were completed in a subset of children recruited until 2015 and aged above 5 and 7 years old, respectively.Patient-reported outcomes in patients with JPsA versus other JIA categories, and in patients with and without psoriasis within JPsA, were tested via multivariable linear regression, adjusted for age at first presentation, gender, disease duration, ethnicity, and number of active joints.ResultsA total of 1653 patients had JIA; the majority (64.7%) were female and median age at onset was 6.5 years (IQR 2.7 - 10.8). A total of 111 (6.7%) were categorised with JPsA, of which 62 (55.9%) were female with median age at onset of 10.2 (IQR 4.3 - 12.5). In those with JPsA, 35% had psoriasis at diagnosis.There were no significant differences between JPsA and non-JPsA in terms of parental global evaluation of wellbeing (p=0.21), CHAQ (p=0.19), pain (p=0.38), CHQ psychosocial (p=0.18), GHQ (p=0.31) or MFQ (p=0.34).Within JPsA, depressive symptom score on the MFQ was higher in patients with psoriasis compared to those without (coefficient=9.8, 95% CI=0.5 to 19.0, p-value=0.04). However, there were no significant differences in parental global evaluation (p=0.4), CHAQ (p=0.3), pain (p=0. 3), CHQ psychosocial score (p=0.5) or GHQ (p=0.7) between those with and without psoriasis in JPsA (Table 1).Table 1.Patient-reported outcomes in children and young people with JPsA with and without psoriasisPatient-reported outcome at JPsA diagnosisOutcomeCoefficient95% confidence intervalp-valueReference – JPsA without psoriasisReferenceReferenceReferenceWellbeing: Parent global (0-10cm)JPsA with psoriasis0.5-0.8, 1.80.45Function: CHAQ (0-3)0.2-0.2, 0.60.28Pain (0-10cm)0.8-0.8, 2.40.34Psychosocial health: CHQ (0-100)-2.4-10.1, 5.30.52Parent psychosocial: GHQ (0-84)-1.3-8.7, 6.10.72Depressive symptoms: MFQ (0-66)9.80.5, 19.00.04ConclusionDespite the differences in clinical features present in JPsA compared to the other JIA subtypes, there were no statistically significant differences in patient-reported outcomes overall at diagnosis. However, within the JPsA group, even when adjusting for age, children with psoriasis at time of arthritis diagnosis reported higher depressive symptom scores compared to those without psoriasis. When treating children with JPsA, attention to diagnosing and treating both arthritis and psoriasis may help mood. If poor mood persists in this subtype, then further allied health care may be required.AcknowledgementsWe thank all the children and young people and their families involved in CAPS, as well as clinical staff and administrators. We also thank the data management team at the University of Manchester (UK). CAPS is funded by Versus Arthritis (UK grant 20542). This report includes independent research funded by the NIHR Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health. KLH is additionally supported by the Centre for Epidemiology Versus Arthritis (UK grant 21755) at the University of Manchester, UK.Disclosure of InterestsJie Man (Jasmine) Low: None declared, Kimme Hyrich Speakers bureau: AbbVie, Grant/research support from: BMS, UCB, and Pfizer, Nophar Geifman: None declared, Stephanie Shoop-Worrall: None declared

Objective.To compare the clinical features and outcome between patients with juvenile psoriatic arthritis (JPsA) and non-JPsA juvenile idiopathic arthritis (JIA).Methods.Fifty-three children with JPsA, 32 with < 5 joints in the first 6 months of disease (oligo–JPsA) and 21 (≥ 5 joints) polyarticular-onset (poly-JPsA) were compared to 53 patients with JIA who were matched by sex, age, date of diagnosis, and articular onset pattern.Results.There was no difference in the percentage of patients between the oligoarticular groups who developed extended oligoarthritis or in the percentage of patients who were positive for antinuclear antibodies. The only differences were that 25% of patients with oligo-JPsA had dactylitis compared to 0% of patients with oligo-JIA (p < 0.01) and 50% had nail pitting as compared to 18.7% (p < 0.05). In polyarticular patients the percentages with dactylitis were similar (19% vs 38%; p = 0.25). The frequency of uveitis was identical in the oligoarticular patients but a higher rate was seen in poly-JPsA compared to poly-JIA (23.8% vs 0%; p = 0.02), while contractures were more frequent in poly-JIA compared to poly-JPsA during the course of the illness (47.6% vs 14.3%; p = 0.03) but not at last followup (14.3% vs 4.7%; p = 0.6). At last followup the mean Childhood Health Assessment Questionnaire scores were similar in both the polyarticular and oligoarticular groups.Conclusion.There were only a few differences between patients with JPsA and JIA regarding disease onset, disease course, and outcome. We suggest that large, longterm prospective studies are required to accurately determine whether subdividing JIA according to psoriasis is worthwhile.

Objective.Children with clinically diagnosed juvenile psoriatic arthritis (JPsA) who were enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry (CARRA-JPsA) were classified according to pediatric International League of Associations for Rheumatology (ILAR) and adult criteria [Classification criteria for Psoriatic Arthritis (CASPAR)]. Data on demographic and clinical features at baseline and 1-year followup were analyzed and compared.Methods.Cross-sectional analysis was performed of CARRA-JPsA patients enrolled between May 2010 and December 2013 and stratified according to age at disease onset (≤ or > 4 yrs). Features of patients fulfilling ILAR and CASPAR criteria were compared at baseline and followup using chi square, Fisher’s exact, Mann-Whitney-McNemar, Wilcoxon signed rank, and t tests, as appropriate.Results.Among 361 children enrolled as CARRA-JPsA, 72.02% had symptom onset at > 4 years of age, with a male predominance and high prevalence of enthesitis. At followup, statistically significant improvements were reported in arthritis, dactylitis, enthesitis, psoriasis, sacroiliitis, and nail pitting, but not in health questionnaire (HQ) scores. Of the patients, 80.5% fulfilled ILAR criteria for JPsA. Fifty-two patients, whose disease fulfilled CASPAR criteria but had not been included in the JPsA cohort, manifested more enthesitis, sacroiliitis, inflammatory bowel disease and uveitis and less psoriasis.Conclusion.The data support division of patients with JPsA into 2 clinical subgroups, according to age at disease onset. Improvement in objective findings did not correlate with changes in HQ scores. Pediatric rheumatologists currently do not diagnose JPsA in all children whose disease manifestations meet CASPAR criteria. Unification of adult and pediatric PsA classification criteria warrants consideration.

Objective.Adult patients with psoriatic arthritis are at increased risk for obesity and metabolic syndrome, but data regarding adiposity in children with juvenile psoriatic arthritis (JPsA) are limited. Our study assessed adiposity in children with JPsA in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry.Methods.Patients with JPsA in the CARRA registry were divided into nonoverweight and overweight groups using recommendations from the US Centers for Disease Control, and differences in demographic and clinical characteristics between groups at baseline and after 1-year followup were assessed using chi-square test, Fisher’s exact test, T test, or Mann-Whitney U test, as appropriate. The prevalence of overweight status in the JPsA registry patients was compared to rheumatoid factor–positive and −negative polyarticular juvenile idiopathic arthritis (RF+polyJIA; RF−polyJIA) registry cohorts and the US pediatric population, using a chi-square goodness-of-fit test.Results.Overweight children represented 36.3% of this JPsA cohort (n = 320). Compared to nonoverweight children, they were significantly older at symptom onset and rheumatologist’s first assessment, and scored significantly worse on patient/physician outcome measures. At 1-year followup, changes in body mass index were not associated with changes in clinical features or outcome measures. The prevalence of overweight and obesity in patients with JPsA was significantly higher than in RF+polyJIA patients, RF−polyJIA patients, and the US pediatric population.Conclusion.In this registry, almost 1 in 5 patients with JPsA were obese and more than one-third were overweight. This is significantly more than expected compared to the US pediatric population, and appropriate longterm followup of this JPsA subgroup is warranted.

Background:Juvenile Psoriatic Arthritis (JPsA) is an inflammatory arthritis associated with irreversible joint damage among the pediatric population, which is associated with psoriasis in most cases.While there are few validated screening tools for diagnosis of arthritis for adult patients with psoriasis, those screening tools were never evaluated in children.Objectives:The aims of this study were to evaluate two screening tools among pediatric patients with psoriasis.Methods:Thirty-nine patients with the diagnosis of psoriasis were administered two screening questionnaires: the new Early Arthritis for Psoriatic Patients (EARP) questionnaire and the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire.All patients were evaluated by a rheumatologist for the diagnosis of JPsA, and the accuracy of the two questionnaires compared.Results:The 4/39 (10.1%) patients diagnosed with JPsA had a PEST questionnaire score of ≥ 3, compared to a median PEST score of the patients without the diagnosis of JPsA of 0 (0-2). Thus both the sensitivity and specificity of the PEST in diagnosing JPsA were 100%.For the EARP questionnaire, 8/39 patients had a screening questionnaire score of ≥ 3, suggestive of JPsA, four were true positive, and four false positive. Thus, the sensitivity and specificity of EARP in diagnosing JPsA were 100% and 89%, respectively.Conclusion:Both the PEST and EARP questionnaires were easy to use and had high sensitivity for pediatric population with psoriasis, however the PEST questionnaire had a higher specificity than the EARP.Disclosure of Interests:None declared.

Juvenile psoriatic arthritis (JPsA) accounts for 1–7% of all cases of juvenile idiopathic arthritis (JIA) and its definition has been a matter of controversy among pediatric rheumatologists for many years. The traditional attribution of JPsA to the spondyloarthropathy group was challenged in the early 1990s, whereas the recent demonstrations of its heterogenous nature have led to questions about its identification as a distinct category in JIA classification. It has been shown that children with the phenotype of JPsA can be divided in two subgroups, one presenting with the features of early-onset ANA-positive JIA, and another that belongs to the spectrum of spondyloarthropathies. The few studies that have compared the clinical characteristics and genetic determinants of JPsA with those of the other JIA categories have obtained contrasting findings. The debate on the categorization of JPsA as a distinct entity within JIA classification is still ongoing and has prompted the revision of its current classification.

BackgroundThe heterogenous presentation and variable clinical response of juvenile psoriatic arthritis (JPsA) to disease-modifying therapies suggests undiscovered subgroups within this disease. Nevertheless, JPsA is often studied under the umbrella of juvenile idiopathic arthritis (JIA), with few studies interrogating JPsA separately. To improve stratified treatment of this rare disease, such subgroups must be uncovered.ObjectivesTo identify novel, phenotypically consistent subgroups of children and young people (CYP) with JPsA at the point of first contact with paediatric rheumatology.MethodsCYP were initially selected if enrolled between January 2001 and December 2019 to the Childhood Arthritis Prospective Study, a UK, multicentre, prospective inception cohort of JIA. Those who had a physician’s diagnosis of JPsA at any time point through the 10-year follow-up were included, to allow for onset of psoriatic signs after initial diagnosis. At initial presentation to paediatric rheumatology, clinical features within the ILAR classification criteria for JPsA were collected: an active joint count and the presence or absence of psoriasis, dactylitis and nail abnormalities. Latent class analysis used these features to identify clusters of disease. Between one and ten clusters were tested and an optimal model selected based on statistical fit.ResultsOf 1,753 CYP with JIA recruited to CAPS within the study period, a total of 161 CYP had ever had a diagnosis of JPsA (n=97 diagnosed as JPsA at initial presentation to paediatric rheumatology). The majority were female (61%), of white ethnicity (94%) and the median age at initial presentation was 10 years (IQR 6, 13).The optimal latent class model identified two clusters of JPsA. An oligoarticular cluster (90%, median active joint count (IQR): 2 (1,5)) had a higher proportion of CYP affected by psoriasis (Cluster 1: 29%, Cluster 2: 14%). A polyarticular cluster (10%, median active joint count (IQR): 20 (16, 27)) had a higher proportion with nail abnormalities (Cluster 1: 8%, Cluster 2: 27%). There were similar proportions of dactylitis among the clusters (Cluster 1: 18%, Cluster 2: 15%) (Figure 1).ConclusionThis study identifies two clusters of JPsA at initial presentation to paediatric rheumatology with differences in key features used to classify this disease. Such subgroups may have different experiences of disease, and future analysis will explore characteristics, alongside disease impact and response to therapy for these groups.Figure 1.Characteristics of two JPsA clusters identified at initial presentation to paediatric rheumatologyAcknowledgementsWe thank all the children and young people and their families involved in CAPS as well as clinical staff and administrators. We also thank the data management team at the University of Manchester (UK). This work is funded by the Medical Research Council (MR/W027151/1), and is also supported by Versus Arthritis (UK grant numbers 20542 & 21755) and the NIHR Manchester Biomedical Research Centre (NIHR203308).Disclosure of InterestsStephanie Shoop-Worrall: None declared, Coziana Ciurtin: None declared, Gavin Cleary: None declared, Flora McErlane: None declared, Laura Coates: None declared, Nophar Geifman: None declared, Kimme Hyrich Speakers bureau: AbbVie, Grant/research support from: BMS and Pfizer.

Approved for public release; distribution is unlimited
The U.S. Army's joint platform allocation tool (JPAT) is an integer linear program that was developed by the Army's Training and Doctrine Command Analysis Center and the Naval Postgraduate School to help inform acquisition decisions involving aerial reconnaissance and surveillance (R&S) resources. JPAT evaluates inputs such as mission requirements, locations of available equipment, and budgetary constraints to determine an effective assignment of unmanned aerial R&S assets to missions. As of September 2013, JPAT is solved using a rolling horizon approach, which produces a sub-optimal solution, and requires substantial computational resources to solve a problem of realistic size. Because JPAT is an integer linear program, it is a suitable candidate for using decomposition techniques to improve its computational efficiency. This thesis conducts an analysis of multiple approaches for increasing JPAT's computational efficiency. First, we reformulate JPAT using Benders decomposition. Then, we solve both the original and decomposed formulations using the simplex and barrier algorithms with multiple size datasets. In addition, we experiment with an initial heuristic solution and other techniques in our attempts to improve JPAT's runtime. We find that while Benders decomposition does not result in significant improvements in computation time for the instances considered in this thesis, initial solution heuristics and other modifications to the model improve JPAT's performance.